200 related articles for article (PubMed ID: 26075237)
1. Progesterone and Src family inhibitor PP1 synergistically inhibit cell migration and invasion of human basal phenotype breast cancer cells.
Xie M; Zhou L; Chen X; Gainey LO; Xiao J; Nanes MS; Hou A; You S; Chen Q
Biomed Res Int; 2015; 2015():426429. PubMed ID: 26075237
[TBL] [Abstract][Full Text] [Related]
2. Progesterone reverses the mesenchymal phenotypes of basal phenotype breast cancer cells via a membrane progesterone receptor mediated pathway.
Zuo L; Li W; You S
Breast Cancer Res; 2010; 12(3):R34. PubMed ID: 20540763
[TBL] [Abstract][Full Text] [Related]
3. The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
Bartscht T; Lehnert H; Gieseler F; Ungefroren H
Cancer Chemother Pharmacol; 2012 Aug; 70(2):221-30. PubMed ID: 22699812
[TBL] [Abstract][Full Text] [Related]
4. Progesterone inhibits the migration and invasion of A549 lung cancer cells through membrane progesterone receptor α-mediated mechanisms.
Xie M; You S; Chen Q; Chen X; Hu C
Oncol Rep; 2013 May; 29(5):1873-80. PubMed ID: 23467643
[TBL] [Abstract][Full Text] [Related]
5. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling.
Waltenberger J; Uecker A; Kroll J; Frank H; Mayr U; Bjorge JD; Fujita D; Gazit A; Hombach V; Levitzki A; Böhmer FD
Circ Res; 1999 Jul; 85(1):12-22. PubMed ID: 10400906
[TBL] [Abstract][Full Text] [Related]
6. Pyrazolo pyrimidine-type inhibitors of SRC family tyrosine kinases promote ovarian steroid-induced differentiation of human endometrial stromal cells in vitro.
Maruyama T; Yamamoto Y; Shimizu A; Masuda H; Sakai N; Sakurai R; Asada H; Yoshimura Y
Biol Reprod; 2004 Jan; 70(1):214-21. PubMed ID: 14522827
[TBL] [Abstract][Full Text] [Related]
7. Progesterone suppresses triple-negative breast cancer growth and metastasis to the brain via membrane progesterone receptor α.
Zhou L; Zhou W; Zhang H; Hu Y; Yu L; Zhang Y; Zhang Y; Wang S; Wang P; Xia W
Int J Mol Med; 2017 Sep; 40(3):755-761. PubMed ID: 28713912
[TBL] [Abstract][Full Text] [Related]
8. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
[TBL] [Abstract][Full Text] [Related]
9. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
[TBL] [Abstract][Full Text] [Related]
10. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects.
Rocha A; Azevedo I; Soares R
J Cell Biochem; 2008 Feb; 103(2):607-14. PubMed ID: 17614352
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
[TBL] [Abstract][Full Text] [Related]
12. Functional involvement of src and focal adhesion kinase in a CD99 splice variant-induced motility of human breast cancer cells.
Lee HJ; Kim E; Jee B; Hahn JH; Han K; Jung KC; Park SH; Lee H
Exp Mol Med; 2002 Jul; 34(3):177-83. PubMed ID: 12216109
[TBL] [Abstract][Full Text] [Related]
13. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
14. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells.
Sánchez-Bailón MP; Calcabrini A; Gómez-Domínguez D; Morte B; Martín-Forero E; Gómez-López G; Molinari A; Wagner KU; Martín-Pérez J
Cell Signal; 2012 Jun; 24(6):1276-86. PubMed ID: 22570868
[TBL] [Abstract][Full Text] [Related]
15. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
Hiscox S; Morgan L; Green TP; Barrow D; Gee J; Nicholson RI
Breast Cancer Res Treat; 2006 Jun; 97(3):263-74. PubMed ID: 16333527
[TBL] [Abstract][Full Text] [Related]
16. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
17. Activation of membrane progesterone receptor-alpha increases proliferation, migration, and invasion of human glioblastoma cells.
González-Orozco JC; Hansberg-Pastor V; Valadez-Cosmes P; Nicolas-Ortega W; Bastida-Beristain Y; Fuente-Granada M; González-Arenas A; Camacho-Arroyo I
Mol Cell Endocrinol; 2018 Dec; 477():81-89. PubMed ID: 29894708
[TBL] [Abstract][Full Text] [Related]
18. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
He H; Hirokawa Y; Levitzki A; Maruta H
Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
[TBL] [Abstract][Full Text] [Related]
19. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
20. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
